MAGNOLIA, Texas, Feb. 4, 2026 /PRNewswire/ — Stratus® Medical, a company focused on advancing radiofrequency (RF) ablation treatment for chronic pain, announced a $10 million Series B financing. The financing was led by Wasatch Health Partners, a healthcare-focused investment firm pursuing growth equity and lower middle-market buyout strategies. Wasatch Health Partners invested through its Growth Fund and previously provided a $25 million convertible debt facility through its Structured Capital platform.
The proceeds from the Series B financing will be used to complete development of the Stratus Medical RF Generator and neurovasis™basivertebral nerve ablation (BVNA) technology, expand and protect the company’s valuable patent portfolio, and fund a clinical study. These high-potential technologies will allow Stratus Medical to better serve its rapidly growing customer base while leveraging the proven and patented NIMBUS® RF Multitined Expandable Electrode (Nimbus) design.
Vertebrogenic low back pain develops when the vertebral endplates in the spine become damaged, often as a result of progressive degeneration over time. Current treatment options include medications, physical therapy, and basivertebral nerve ablation (BVNA). It is estimated that more than five million people in the United States suffer from vertebrogenic back pain.
The Stratus Medical RF Generator and neurovasis BVNA technologies are under development and have not been submitted, evaluated, or cleared by the FDA.
Luke Larsen, Vice President at Wasatch Health Partners, said, “We are pleased to expand our partnership with Stratus Medical. The company has demonstrated strong execution, consistent revenue growth, and meaningful progress across technology development and clinical initiatives. We believe the management team is well positioned to continue building on this momentum.”
Bret Boudousquie, CEO of Stratus Medical, commented, “We appreciate the long-term relationship with Wasatch Health Partners and their continued belief in our mission to help chronic pain patients by advancing RF technology. Stratus Medical is proud to work with outstanding physicians, hospitals, and ASCs, and we are anxious to deliver additional value with our future RF technologies that this financing enables us to complete.”
Doug Beall, MD, Director of Interventional Radiology, Clinical Radiology of Oklahoma, commented, “I started using Nimbus in 2020 for radiofrequency ablation pain treatments due to its larger ablation zone and ease of use. In 2022, I started providing scientific input on the neurovasis project. In 2024, my colleagues and I published the first scientific article describing the neurovasis BVNA technique utilizing CT reconstruction to assess device placement. This technology builds on the Nimbus multitined design and has the potential to offer faster, easier-to-use RF treatments and cost reductions for hospitals and ASCs.”
Informazioni su Stratus Medical
Stratus Medical is a medical device company focused on reducing pain and improving the quality of life for chronic pain patients through innovation. The Company has been recognized for revenue growth and innovation by Deloitte Technology Fast 500, Pepperdine Most Fundable Companies, and The Houston Business Journal. Nimbus has rapidly gained market share in the US and other countries based on ease of use, reduced procedure times, and its large-volume lesion designed to provide sustained pain relief. Stratus Medical is headquartered in Magnolia, Texas.
About Wasatch Health Partners
Wasatch Health Partners is a healthcare-focused investment firm investing in medical device, life science, and outsourced medtech, and pharmaceutical services companies through growth equity, lower middle-market buyouts, and structured capital strategies. The firm is headquartered in Salt Lake City, Utah.
Contatto con i media
Cody Jorgensen
Comunicazioni di marketing
Stratus Medical
346-703-0642
cody@stratusmedical.com
https://stratusmedical.com
English English 
Italiano
Português do Brasil
Português
Español
العربية
Background:
Radiofrequency neurotomy (RFN) can be an effective treatment for patients with chronic neck pain and cervicogenic headaches resistant to conservative care. However, the degree and duration of pain relief after RFN is dependent upon the thoroughness of target nerve coagulation.
Case Report:
This is a case of a 37-year-old patient with debilitating neck pain and headaches following a motor vehicle accident. Successful local anesthetic block of the third occipital nerve (TON) confirmed pain of C2-C3 facet joint origin. An initial RFN treatment of the TON, using standard 18G electrodes in bipolar mode, resulted in complete symptom amelioration for 8 months. Repeat RFN, using the same electrode configuration, was unsuccessful in alleviating the severe neck pain and headaches, and produced no demonstrable sensory loss in the distribution of the TON. RFN was then performed using the NIMBUS® electrosurgical RF multitined expandable electrode, which provides a larger zone of coagulation in volume than standard RFN electrodes even when used in bipolar configuration.
Conclusion:
The NIMBUS procedure resulted in successful coagulation of the TON with sensory loss in the TON distribution and reinstatement of palliative relief.
